

# Michela Giustozzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6239821/publications.pdf>

Version: 2024-02-01

51  
papers

938  
citations

471477

17  
h-index

501174

28  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1493  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 215-229.	2.6	104
2	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1128-1136.	3.4	93
3	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2019, 50, 2168-2174.	2.0	59
4	Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1142-1154.	3.8	54
5	Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment. <i>Blood Reviews</i> , 2021, 50, 100864.	5.7	50
6	Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: A meta-analysis. <i>Thrombosis Research</i> , 2014, 134, 1265-1271.	1.7	47
7	Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study. <i>International Journal of Cardiology</i> , 2018, 269, 152-157.	1.7	35
8	Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 981-991.	3.4	33
9	Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 833-841.	3.8	31
10	Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. <i>Thrombosis Research</i> , 2018, 170, 175-180.	1.7	31
11	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. <i>Stroke</i> , 2022, 53, 2620-2627.	2.0	28
12	Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 236, 363-369.	1.7	27
13	Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1217-1228.	3.8	27
14	Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. <i>International Journal of Cardiology</i> , 2019, 281, 56-61.	1.7	23
15	Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. <i>Haematologica</i> , 2015, 100, e35-e38.	3.5	20
16	Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 439-453.	2.1	20
17	Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. <i>Thrombosis and Haemostasis</i> , 2020, 120, 847-856.	3.4	20
18	Safety of catheter ablation of atrial fibrillation in cancer survivors. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 60, 419-426.	1.3	20

#	ARTICLE	IF	CITATIONS
19	Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation. <i>Clinical Drug Investigation</i> , 2021, 41, 43-51.	2.2	18
20	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2751-2759.	3.8	18
21	Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 336-339.	2.1	17
22	Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. <i>Thrombosis Research</i> , 2019, 177, 33-41.	1.7	15
23	Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. <i>European Journal of Internal Medicine</i> , 2016, 33, 42-46.	2.2	14
24	ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 4873-4883.	5.2	13
25	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. <i>European Journal of Internal Medicine</i> , 2021, 88, 43-51.	2.2	10
26	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102280.	7.7	10
27	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 527-535.	2.1	9
28	Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2069-2071.	1.8	8
29	Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management. <i>European Journal of Internal Medicine</i> , 2020, 82, 18-20.	2.2	7
30	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2347-2354.	2.0	7
31	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2021, 52, 1450-1454.	2.0	7
32	Total parenteral nutrition-induced Wernicke's encephalopathy after oncologic gastrointestinal surgery. <i>Open Medicine (Poland)</i> , 2020, 15, 709-713.	1.3	7
33	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. <i>European Stroke Journal</i> , 2020, 5, 374-383.	5.5	6
34	Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding. <i>Thrombosis Research</i> , 2021, 208, 138-144.	1.7	6
35	Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 336-343.	4.9	6
36	Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation. <i>Cerebrovascular Diseases Extra</i> , 2020, 10, 44-49.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1063-1069.	2.4	4
38	Management of Anticoagulant Treatment and Anticoagulation-Related Complications in Nonagenarians. <i>Hamostaseologie</i> , 2020, 40, 292-300.	1.9	4
39	Perirectal Hematoma and Intra-Abdominal Bleeding after Stapled Hemorrhoidopexy and STARR: A Proposal for a Decision-Making Algorithm. <i>Medicina (Lithuania)</i> , 2020, 56, 269.	2.0	4
40	Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 391-394.	1.0	3
41	Beyond the guidelines: Novelties, changes and unsolved issues from the 2019 ESC guidelines on pulmonary embolism. <i>European Journal of Internal Medicine</i> , 2020, 72, 1-4.	2.2	3
42	Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis. <i>European Journal of Internal Medicine</i> , 2021, 83, 14-20.	2.2	3
43	Patients with Atrial Fibrillation receiving NOACs: The boundary between appropriate and inappropriate dose. <i>European Journal of Internal Medicine</i> , 2021, 88, 25-27.	2.2	3
44	Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?. <i>Thrombosis Research</i> , 2018, 164, S168-S171.	1.7	2
45	Non-cirrhotic Extra-Hepatic Porto-Systemic Shunt Causing Adult-Onset Encephalopathy Treated with Endovascular Closure. <i>Digestive Diseases and Sciences</i> , 2020, 65, 946-951.	2.3	2
46	Thromboembolic Complications in Covid-19: From Clinical Scenario to Laboratory Evidence. <i>Life</i> , 2021, 11, 395.	2.4	2
47	Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation. <i>Data in Brief</i> , 2019, 23, 103794.	1.0	1
48	The possible clinical impact of a threshold left atrial diameter associated with new AF in ESUS patients. <i>European Journal of Internal Medicine</i> , 2020, 75, 19-20.	2.2	1
49	Shock and diffuse ST-elevation in a patient with coronavirus disease-2019 disease. <i>Journal of Cardiovascular Echography</i> , 2020, 30, 223.	0.4	1
50	Anticoagulation for atrial fibrillation in patients with active cancer: Reply to the "Letter to the Editor" from Dr. Sorigue et al.. <i>International Journal of Cardiology</i> , 2019, 280, 97.	1.7	0
51	The role of computed tomography angiography 3D imaging in postoperative hemorrhage after groin mesh hernioplasty during anticoagulation therapy. <i>Minerva Surgery</i> , 2021, 76, 286-287.	0.6	0